Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Pfizer
Pfizer
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Pheon Therapeutics
Merck Sharp & Dohme LLC
Tagworks Pharmaceuticals BV
National Cancer Institute (NCI)
Iovance Biotherapeutics, Inc.
St. Jude Children's Research Hospital
University of Alabama at Birmingham
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Turning Point Therapeutics, Inc.
Taiho Oncology, Inc.
NRG Oncology
Alterome Therapeutics, Inc.
Boston Scientific Corporation
Peking University People's Hospital
SillaJen, Inc.
Eastern Cooperative Oncology Group
Case Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Roswell Park Cancer Institute
ToLymph Inc.
Emory University
Nuvectis Pharma, Inc.
George Washington University
AstraZeneca
AstraZeneca
Avenzo Therapeutics, Inc.
Shanghai Pulmonary Hospital, Shanghai, China
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Emory University
Auricula Biosciences Inc.
DualityBio Inc.
NATCO Pharma Ltd.
Tanabe Pharma America, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Yonsei University
Yonsei University
M.D. Anderson Cancer Center
Mayo Clinic
Cedars-Sinai Medical Center
Emory University